==== Front J Transl Med J Transl Med Journal of Translational Medicine 1479-5876 BioMed Central London 2662 10.1186/s12967-020-02662-9 Review Hypoxic exosomes orchestrate tumorigenesis: molecular mechanisms and therapeutic implications Jafari Reza 12 Rahbarghazi Reza 34 Ahmadi Mahdi 5 Hassanpour Mehdi 367 http://orcid.org/0000-0001-8175-3730Rezaie Jafar Rezaie.j@umsu.ac.ir 1 1 grid.412763.50000 0004 0442 8645Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Shafa St, Ershad Blvd, P.O. BoX: 1138, 57147 Urmia, Iran 2 grid.412763.50000 0004 0442 8645Department of Immunology and Genetics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran 3 grid.412888.f0000 0001 2174 8913Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 4 grid.412888.f0000 0001 2174 8913Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran 5 grid.412888.f0000 0001 2174 8913Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 6 grid.412888.f0000 0001 2174 8913Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran 7 grid.412888.f0000 0001 2174 8913Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran 10 12 2020 10 12 2020 2020 18 47419 6 2020 3 12 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.The solid tumor microenvironment possesses a hypoxic condition, which promotes aggressiveness and resistance to therapies. Hypoxic tumor cells undergo broadly metabolic and molecular adaptations and communicate with surrounding cells to provide conditions promising for their homeostasis and metastasis. Extracellular vesicles such as exosomes originating from the endosomal pathway carry different types of biomolecules such as nucleic acids, proteins, and lipids; participate in cell-to-cell communication. The exposure of cancer cells to hypoxic conditions, not only, increases exosomes biogenesis and secretion but also alters exosomes cargo. Under the hypoxic condition, different signaling pathways such as HIFs, Rab-GTPases, NF-κB, and tetraspanin are involved in the exosomes biogenesis. Hypoxic tumor cells release exosomes that induce tumorigenesis through promoting metastasis, angiogenesis, and modulating immune responses. Exosomes from hypoxic tumor cells hold great potential for clinical application and cancer diagnosis. Besides, targeting the biogenesis of these exosomes may be a therapeutic opportunity for reducing tumorigenesis. Exosomes can serve as a drug delivery system transferring therapeutic compounds to cancer cells. Understanding the detailed mechanisms involved in biogenesis and functions of exosomes under hypoxic conditions may help to develop effective therapies against cancer. Keywords HypoxiaExosomesHIFTumor microenvironmentTumorigenesisissue-copyright-statement© The Author(s) 2020 ==== Body Background Hypoxia, a condition of insufficient oxygen, is a common feature of numerous solid tumors, related to tumor development, therapy resistance, and mortality [1]. Tumor cells in the microenvironment encounter low oxygen levels because of insufficient oxygen flow and physiological anomalies in tumor vessels, resulting in normoxic, hypoxic, and also necrotic regions [2]. In most solid tumors, the average concentration of oxygen is near 10 mmHg, whereas in the other tissues it reaches 40 and 60 mmHg [3]. Tumor cells juxtaposed to the normal vessels are functional, whereas cells situated around 150 μm from the vasculature bed may undergo necrosis and atresia [4], however, cells are located between these two cell populations habituate to an insufficient oxygen environment, hypoxia. Generally, cells located in a diameter of approximately 1 mm undergo genetic, molecular, and metabolic changes. These cells could reorganize the microenvironment appropriate for growth, metastasis, and therapy resistance [5]. In this situation, by the production of pro-angiogenic factors, tumor cells can induce angiogenesis for supplying nutrients and oxygen and removing waste. Besides, increased angiogenesis in tumor mass provides a way for tumor cells to migrate and metastasize [6]. In response to a hypoxic condition, the transcription profile of tumor cells such as hypoxia-inducible factors (HIFs), the key factor involved in regulating hypoxic condition, are altered [7]. HIFs, the dimeric proteins, are composed of a constitutive subunit named HIF-1β and an oxygen-regulated α-subunit (HIF-1, 2, 3α) [8]. The activity of HIF-1α is dynamic and related to the availability of oxygen. In the presence of oxygen, HIF-1 α is degraded by the proteasome system; so that, HIF-1α is hydroxylated by prolyl hydroxylases (PHD), in keeping, von Hippel-Lindau (VHL) recognizes the hydroxylated HIF-1α. This event subsequently ubiquitinates HIF-1α for degradation by the 26S proteasome [9, 10]. PHDs are inactive in a hypoxic condition and allow HIF-1α to link to the HIF-1β subunit. According to previous studies, HIFs are active in almost solid tumors. HIFs regulate different signaling pathways, which are implicated in the cell viability, proliferation, epithelial-to-mesenchymal transition (EMT), angiogenesis, metastasis, and therapy resistance [11]. However, other pathways including mammalian target of rapamycin (mTOR), phosphatidylinositol 3-kinases (PI3K)-Akt, Wnt/β-catenin, nuclear factor-κB (NF-κB), mitogen-activated protein kinases (MAPK), and NADPH oxidase (NOX) facilitate the adaption of tumor cells to hypoxia [1, 12, 13]. Besides, HIFs have been shown to facilitate exosomes biogenesis and secretion [14]. Exosomes a subfamily of extracellular vesicles (EVs) mediate intercellular communication by carrying different biological molecules among cells. These vesicles contain various biological molecules like proteins, RNAs (coding and non-coding RNAs), DNAs, and lipids, regulating activation of different signaling pathways in recipient cells located nearby or distant tissues [15, 16]. It has been shown that exosomes derived from tumor cells participate in modulating the tumor microenvironment and promoting tumorigenesis [17, 18]. Confirmed that, hypoxia induces exosomes biogenesis and secretion and thereby promotes tumor intercellular communication, representing the key role of exosomes in hypoxic tumors [14, 19]. The majority of experiments discussed in this review used 1% O2 as a hypoxic model that generally called the hypoxic condition, if not, we explained the condition. In the present review, we discuss exosomes biogenesis and loading and also possible underlying mechanisms under hypoxic. Also, we describe the key roles of hypoxic in tumorigenesis and tumor-therapy. Tumor microenvironment The tumor microenvironment is a dynamic environment around a tumor, containing the blood vessels, fibroblasts, immune cells, the extracellular matrix (ECM), and signaling molecules that support proliferation, growth, metastasis, and therapy resistance of tumor cells. Tumor cell proliferation, death, invasion, migration, angiogenesis, metabolic reprogramming, immune evasion, are all regulated by the complex interaction inside the tumor microenvironment. In this regard, autocrine, paracrine, and juxtacrine communication network orchestrate these biological functions. Paracrine-mediated communication plays pivotal roles in signal transduction between neighboring and distant cells [20–22]. Non-tumor cells including fibroblasts, endothelial cells (ECs), and immune cells contribute to tumor microenvironment interaction and are affected by tumor soluble factors, and their fate goes through tumor-like modifications, persistently accommodate to the tumor microenvironment and support tumor growth. In the tumor microenvironment, fibroblasts are motivated into cancer-associated fibroblasts (CAFs), these cells are the most resident stromal cells in the tumor microenvironment, producing an ECM that vary common ECM in inflexibility and arrangement properties that facilities migration and invasion of tumor cells [23]. In the tumor microenvironment, hypoxia induces tumor cells to produce angiogenic factors, which in turn affect ECs and up-regulate angiogenesis [24, 25]. In the tumor microenvironment, the resident immune cells demonstrate multiplicity and could suppress the immune responses. Also, anti-inflammatory molecules can inhibit the immune system, which is involved in the suppression of cancer cells [26, 27]. These factors and cells make the tumor microenvironment a complex system and resistant to different therapies [28, 29]. Biogenesis of EVs The term EVs refers to nano-micro-sized heterogeneous vesicles released from cells via intrigue mechanisms [15]. EVs generally comprise three classes of vesicles including exosomes, ectosomes, and apoptotic bodies [30]. Exosomes are 30–150 nm vesicles that originated from multivesicular bodies (MVBs) located in the cytoplasm, and thus, secreted into the extracellular milieu following the fusion of MVBs with the plasma membrane [31] (Fig. 1). In general, MVBs have three possible fates [15, 32], including; (i) the fusion of MVBs with the plasma membrane and secretion of exosomes, (ii) fusion with lysosome and degradation of exosomes, and (iii) back-fusion with the plasma membrane and recycling the biomolecules to the plasma membrane. Upon secretion into the extracellular milieu, exosomes can deliver their cargo to target cells and affect their fate, function, and morphology [33, 34] (Fig. 1). Ectosomes are also known microvesicles (MVs), ranging from 100 to 1000 nm, shed directly from the plasma membrane [30] (Fig. 1). Similar to the exosomes loading process, proteins and lipids and of the membrane- are directed into sites of MVs budding. For example, the oligomeric cytoplasmic proteins are anchored to the plasma membrane lipids and also have a high affinity for lipid rafts, therefore these proteins can enter into MVs [35, 36]. MVs exhibit common markers such as Annexin V, Flotinin-2, CD40, CD62, and integrins.Fig. 1 Biogenesis and secretion of exosomes. Exosomes originate from multivesicular body (MVB) and release into the extracellular matrix upon fusion of MVB with the plasma membrane. One secreted, exosomes can reach to target cells through three possible ways. Microvesicles shed directly from the plasma membrane. N: nucleus Once EVs are secreted into the extracellular milieu, target cells can uptake these nano-sized particles. The entrance of EVs into the target cells causes phenotypic and functional changes, affecting normal and pathological states [30] (Fig. 1). According to previous studies, EVs can reach target cells by vesicle internalization, receptor-ligand interaction, and direct fusion with the target cell membrane [30, 33, 37] (Fig. 1). Vesicle internalization may comprise such different mechanisms as endocytosis, pinocytosis, and phagocytosis. In the receptor-ligand interaction way, molecules of EVs surface interact with corresponding molecules on the target cells' plasma membrane [38, 39]. In the direct fusion way, EVs membrane fuse with target cell membrane similar to conventional membrane fusion process by which EVs cargo discharged into the cytoplasm of target cells. Overall, EVs uptake is complex and possibly depends on the types of EVs and target cells, and they may be related to the downstream effects and signaling pathways mediated by EVs [37]. Furthermore, it is not clear that these ways synergically or independently are engaged by cells. Hypoxia promotes exosomes biogenesis Hypoxia has been shown to induce EVs biogenesis and secretion. Wang and co-workers, for example, declared that exposure of breast cancer cells to hypoxia conditions results in producing more MVs via HIF/RAB22A signaling [40]. Similarly, King et al. [41] confirmed that incubation of different breast cancer cell lines; such as MCF-7, SKBR-3, and MDA-MB-231 cells with fair (1% O2) and severe (0.1% O2) hypoxia increased exosomes biogenesis and secretion. They also confirmed the key role of HIF in inducing exosomes biogenesis. However, the detailed mechanisms by which HIF mediates exosomes biogenesis are not fully clear. Besides, hypoxia can change the type of cargo and function of exosomes. Kucharzewska et al. [42], for example, showed that glioma cells cultured under hypoxia condition produce exosomes containing various mRNAs and proteins such as IL-8, caveolin 1, matrix metalloproteinases (MMP), PDGFs, and lysyl oxidase, which are involved in angiogenesis. However, hypoxia can induce exosome biogenesis in non-cancerous cells. Zhang et al. [14] demonstrated that hypoxia increased exosome secretion from renal proximal tubular cells via HIF-1 signaling. Similarly, mesenchymal stem cells (MSCs) produce abundantly exosomes upon exposure to hypoxia [43, 44]. These facts show that hypoxic stress can induce biogenesis and alter exosomal cargo. The underlying molecular mechanisms regulating the exosome loading and secretion under the hypoxic condition are not fully understood yet. However, under hypoxia, few of the pivotal pathways may involve in exosomes biogenesis, which is explained in the next sections. HIFs signaling In hypoxia, HIF-α protein is increased in the cytoplasm and then moves to the nucleus. In the nucleus, it links to the HIF-β subunit and another expression regulators such as the co-activators p300/CBP. Then, this complex binds to the conserved hypoxia-responsive element (HRE) for the expression of genes [45]. HIFs both directly and indirectly mediate the formation of exosomes. Previous studies showed that HIF-1α is involved in MVs and exosome biogenesis in different cell lines such as tumor and non-tumor cells [16, 20, 22]. A mediator molecule that HIF-1 regulates exosome biogenesis under hypoxia is pyruvate kinase 2 (PKM2) enzyme [46], which facilities the progression of the final step within glycolysis, the dephosphorylation of phosphoenolpyruvate to pyruvate, and it participates in ATP production within the glycolytic cycle [47]. We know that the tumor environment represents a high level of lactate as a result of glycolysis. In this regard, there is evidence that PKM2 phosphorylates synaptosome-associated protein 23 (SNAP-23), a protein associated with the synaptosome/SNARE complex, and increases secretion of exosomes [48]. Blocking of glycolysis has been confirmed to diminish the number of exosomes while increasing glycolysis with TNF-α enhanced the number of exosomes [48]. Under hypoxia conditions due to higher glycolysis, the accumulation of lactate causes the acidic condition in the extracellular environment. The acidic pH increases exosome secretion while alkaline pH decreases exosome abscission. As matter of fact, the loading of protein and RNA into exosome is affected by the pH of the environment [49, 50]. Rab-GTPases signaling Different Rab proteins regulate the intracellular trafficking of MVBs/exosomes [15]. Rab-GTPases belong to the Ras superfamily of small GTPases, which are associated with the vesicles and the inner side of the plasma membrane, participating in intracellular trafficking of vesicles [51]. The Rab proteins have two distinct forms as an active form (GTP-bound) and an inactive form (GDP-bound. Rab- GTP-bound form is active and associated with effector proteins, and mediate formation and movement of vesicles incorporation with actin and tubulin [52]. Dorayappan et al. [53] declared that hypoxia could up-regulate STAT3 in ovarian cancer cells. STAT3 regulates the expression of Rab27a and Rab7 molecules; thus increases exosomes biogenesis. Panigrahi et al. [54] showed that Rab5 protein was accumulated around the perinuclear region of prostate cancer cells upon exposure to the hypoxic condition. RAb5 mediates the movement of the endocytosis vesicles from the plasma membrane to early endosomes and also the fusion of early endosomes with each other, proposing a key role of Rab5 in MVBs development and, subsequently promoting exosome biogenesis [54]. Hypoxia can increase the expression of the RHO-associated protein kinase (ROCK) gene, a pivotal enzyme in remodeling actin and cytoskeleton components [55]. ROCK contributes to MVs biogenesis [56], however, it was demonstrated that RhoA can drive the ROCK signaling, which subsequently leads to an induces in exosome biogenesis in various tumor cells [56]. NF-κB signaling The exact effect of hypoxia on NF-κB expression/induction is not clear yet. However, there is evidence that PHDs regulate the expression of NF-κB under a hypoxic condition. The direct effect of NF-κB signaling on exosome biogenesis is not fully discovered so far. Hypoxia can induce the NF-κB signaling pathway, which in turn impacts the exosome cargo loading process. For example, Yang et al. [57] declared that suppression of NF-κB could alter the content of the redox modulating enzymes in exosomes derived from sera of NF-κB knockout mice. Inhibition of NF-κB by aspirin leads to a significant decrease in exosomes biogenesis and secretion [57]. Other molecules may induce exosome biogenesis. Formation of the reactive oxygen species under hypoxic conditions can induce exosome release. Hedlund et al. [58], for example, indicated that under oxidative stress (H2O2 treatment) Jurkat cells and Raji cells abundantly secrete exosomes. Besides, the authors showed that the exosomes' secretion rate of both the cell lines was increased upon the incubation of cells with thermal stress conditions. Tetraspanin signaling Tetraspanin proteins including CD9, CD63, CD37, CD82, and CD81, which are widely used as markers for exosomes, have been shown to facilitate exosome formation during the hypoxic condition. A hypoxia-regulator factor is located in the upstream region of the mouse CD82 gene that is up-regulated by HIF under hypoxia [59]. By overexpressing CD9 and CD82 molecules in HEK 293T cells, Chairoungdua and co-workers confirmed that exosomes production significantly increase [60]. Other key molecules including NOX2 and PI3K/mTOR axis are enriched in hypoxic cells-derived exosomes [61, 62], however, the exact role of them in exosomes biogenesis remains unclear. Hypoxia can change exosomes cargo Hypoxia can alter exosomes cargo. For example, by in vitro and in vivo, Jung et al. [63] showed that exosomes derived from hypoxic mouse breast cancer cells contain abundantly miR-210 that is involved in regulating vascular remodeling-related genes, including PTP1B and Ephrin A3. Similarly, Ding et al. [64] reported that inducing hypoxic stress (1% O2) on SKOV3 ovarian cancer cells led to an increase in the exosomal miR-210 level. The authors concluded that miR-210 increased SKOV3 ovarian cancer cells' mobility and progression. HIF-1α interacts with HRE, which is located on the proximal end of miR-210 and directs it into exosomes [65]. Hypoxic colorectal cancer (CRC) cells release exosomes containing a higher level of Wnt4 that increase the normoxic (21% O2) CRC cell migration behavior and invasion rate via HIF-1α signaling [66]. Furthermore, exosomal Wnt4 increases β-catenin transposition to the nucleus in normoxic CRC cells. The activation of the β-catenin signaling pathway plays a pivotal role in the motility and invasion of normoxic CRC cells. In another study, human pancreatic cancer cells such as PCA LNCaP and PC3 were cultured under hypoxic (1% O2) or normoxic (21% O2) conditions, and their exosomes were isolated from conditioned media. Immunoblotting analysis showed that the protein levels of CD63, CD81, HSP90, HSP70, and Annexin II were increased in hypoxic exosomes as compared to normoxic ones [67]. Exosomes released from hypoxic U87MG glioblastoma cells contain an elevated level of some proteins like thrombospondin-1 (TSP1), VEGF, and protein-lysine 6-oxidase (LOX) that promote growth, metastasis, and angiogenesis of tumor [68]. Using hypoxia-resistant multiple myeloma (HR-MM) cells, Umezu and colleagues team found that these cells abundantly produce exosomes with distinct cargo following incubation with the chronic hypoxic condition. They showed that these exosomes are enriched with miR-135b as compared to those of normoxic cells [69]. The impact of hypoxia on exosomes cargo derived from different cancer cells has been studied, and we summarized a list of the altered cargo of exosomes under hypoxic condition in Table 1.Table 1 Altered cargo of exosomes under hypoxic condition Cancer Breast Ovarian Pancreas Myeloma Gliablastoma Prostate Colorectal Cell line MCF7, SKBR3, and MDA-MB 231/ 4T1 SKOV3, HO-8910 BxPC-3 and AsPC-1 RPMI8226, KMS-11, and U266 U87MG LNCaP and PC3 cells LNCaP, 22Rv1, PC3, and PWR-1E HT29 and HCT116 CRC patients Hypoxic condition 1% O2 and 0.1% O2 1% O2 1% O2 1% O2 1% O2 1% O2 1% O2 Cargo (Increased) miR-210 [41, 63] miR-21–3p, miR-125b-5p, and miR-181d-5p [132] miR-21 [133] miR-135b [134] HIF mRNA, LOX, TSP1, VEGF, disintegrin, MMP, and ADAMTS1 [68] MMPs, IL-8, PDGFs, caveolin 1, and lysyl oxidase [107] CD63, CD81, HSP90, HSP70, and Annexin II [67] Triglycerides, omega-6 fatty acids, linoleic acid, arachidonic acid, palmitic acids, stearic acids, and linoleic acids [135] lactic acid [136] Wnt4 [137] miR-210 [108] Role of hypoxic exosomes in tumor cell metastasis Metastasis, relocation of tumor cells from the origin site to a secondary location, is an essential factor for cancer growth [70]. Tumor cells release exosomes with aggressive properties that can promote tumorigenesis via increasing metastasis upon reach to recipient cells [71]. The induction of epithelial-mesenchymal transition (EMT) in tumor cells is a critical event in the initiation of metastasis [72]. During the EMT process, the tumor cells reorganize their cytoskeleton and acquire a mesenchymal-like phenotype, which enables them for migration and invasion to the new locations [73]. In this scenario, the E-cadherin molecules are down-regulated, which is pivotal for the loss of epithelial phenotype [74]. Thus, loss of E-cadherin is associated with the reduction of cell-to-cell contact, the disruption of catenin/ E-cadherin interaction, abnormal β-catenin signaling, and finally cytoskeleton reorganization. Collectively, these events cause losing epithelial shape and acquiring a migratory phenotype in tumor cells [75]. A growing body of evidence showed that hypoxic tumor cells secrete exosomes promoting the migration ability and invasion rate of different tumor cells. For example, it was reported that exosomes collected from conditioned media of hypoxic prostate cancer cell contain several proteins that down-regulated adherents molecules in naïve LNCaP and PC3 prostate cancer cells, which, in turn increased the migration and invasiveness of cells, thus prompting metastasis in vitro [67]. The authors also showed that these exosomes down-regulated E-cadherin coincided with the up-regulation of nuclear and cytoplasmic β-catenin in prostate cancer cells, indicating an increase in the invasiveness, and stemness of prostate cancer cells. Xue et al. [76] found that hypoxia increased the loading of lncRNA-UCA1 into exosomes of bladder cancer cells. These exosomes promoted the growth and migration of bladder tumor cells both in vitro and animal models. Besides, they showed that the expression levels of lncRNA-UCA1 in blood exosomes of patients with bladder cancers were higher in comparison with the healthy ones. Similarly, Li and co-workers showed that exosomes isolated from hypoxic oral squamous cell carcinoma could induce metastasis in normoxic cells. Further scrutiny revealed that these exosomes abundantly contain miR-21, which was responsible for tumorigenesis via regulating the expression of E-cadherin, snail, and vimentin in target cells [77]. Besides, exosomes derived from hypoxic-treated hepatocellular cancer cells are enriched with linc-RoR that promote migration and metastasis of tumor cells via a miR-145/HIF-1α signaling pathway in vitro [78]. LMP1-positive exosomes derived from nasopharyngeal carcinoma cells can increase metastasis in recipient nasopharyngeal cells via transporting HIF1α and inducing EMT phenotype [79]. The authors demonstrated that HIF1α altered the expression of E- and N-cadherins which is associated with EMT and led to increased migration of cells in vitro. The results obtained from Wang et al. [80] study showed that hypoxic exosomes derived from metastatic small cell lung cancer cells (NCI-H1688) induced migration of tumor cells through TGF-β and IL-10 in vitro. Several experiments have been carried out to investigate the effect of hypoxic exosomes on tumor invasiveness and metastasis (Table 2).Table 2 Roles of exosomes derived from hypoxic tumor cells in cancer Cancer Cell line Hypoxic condition Exosome cargo Mechanism Function Colorectal HT29 and HCT116 1% O2 Wnt4 Up-regulates β-catenin nuclear translocation in endothelial cells Increase angiogenesis [137] Glioblastoma multiforme U87MG 1% O2 TF induces TF/VIIa-mediated PAR-2 activation in endothelial cells Increase angiogenesis [138] Renal Caki-1, KMRC-1, OSRC-2 and 786-O cells 1% O2 CA9 Increases its target MMP2 Increase angiogenesis [139] Prostate PCA LNCaP and PC3 cells 1% O2 Proteins ND Increase invasion and migration [67] Nasopharyngeal CNE1 and CNE2 TW03, C666 and CNE2 and the NP69 1% O2 1% O2 MMP13 HIF-1α miR-24-3p ND Induces EMT ND Increase invasion and migration [140] Modulate immune response [141] Lung and leukemia IGR-Heu lung carcinoma cell line / K562, NK92, and NKD cell lines 0.1% O2 TGF-β1 and miR-23a TGF-β1 suppresses NKG2D, and miR-23a directly inhibits CD107a Modulate immune response [142] Bladder 5637 cells 1% O2 linc-UCA1 Induces EMT Increase invasion and migration [143] Hepatocellular HepG2, Hep3B, PLC-PRF5 and Huh-7 21% O2 linc-RoR ND Increase invasion and migration [78] Breast cancer 4T1 0.1% O2 miR-210 Suppresses the expression of Ephrin A3 and PTP1B Increase angiogenesis [63] ovarian SKOV3 1% O2 miR-940 Induces M2-type macrophages exhibiting CD163 and CD206 markers Modulate immune response [89] lung A549, H1299, and HCC827 1% O2 miR-494 miR-23a Suppresses PTEN and activates Akt/eNOS pathway in endothelial cells Down-regulating PHD1, PHD2 and ZO-1 Increase angiogenesis [93] Increase angiogenesis [92] Leukemia K562 1% O2 miR-210 Inhibits the expression of Ephrin A3 Increase angiogenesis [101] Oral squamous cell SCC-9 and CAL-27 1% O2 miR-21 Induces EMT Promote invasion and migration [144] Multiple myeloma RPMI8226, KMS-11, and U266 1% O2 miR-135b Down-regulates FIH-1 Increase angiogenesis [134] Role of hypoxic exosomes in modulating immune responses Modulating immune responses is vital for the invasion and formation of a new niche for the progress of metastasis [81]. Exosomes from different tumor cells have been shown to modulate the immune system via different ways such as suppression of NK cells activity, inducing T-cell apoptosis, down-regulating IFN-γ-inducible class II expression of macrophages, and regulating the differentiation of monocytes into the myeloid-derived suppressor cells (MSDCs), which collectively leads to immunosuppressive function and the cancer development [82, 83] (Fig. 2). Exosomes from hypoxic nasopharyngeal carcinoma (NPC) cells contain miR-24-3p that inhibit T-cell proliferation, Th17, and Th1 differentiation; and promote the differentiation of regulatory T-cells (Tregs) [84]. Exosomes derived from breast cancer cells directly inhibited the T-cell survival and the NK cell function, consequently, the immune response was inhibited against tumor cells in pre-metastatic organs [85]. Exosomes from lung cancer cells transfer miRs that inhibit the genes related to the Toll-like receptor (TLR) family in macrophages. This event induces the production of proinflammatory cytokines that supports enhanced tumor dissemination [86]. Tumor-derived exosomes from plasma of head and neck squamous cell carcinoma patients contain CD73 and CD39 molecules, which participate in the production of adenosine from ATP. Adenosine is involved in suppressing the activity of activated B cells by converting the motivated B-cells into regulatory B-cells [87]. Also, Liu et al. [88] demonstrated that exosomes from mouse breast and melanoma tumor cells induced the differentiation of myeloid precursor cells towards MSDCs. This phenomenon promotes tumor exosome-mediated expansions of MDSCs and tumor metastasis. Incubation of epithelial ovarian cancer with the hypoxic condition may promote the loading of miR-940 into exosomes. These exosomes induce macrophage polarization by up-regulating the expression of the M2-type markers like CD206 and CD163. These findings demonstrated that exosomes transferred miR-940 to macrophages and induced macrophages to an M2-like phenotype, which is favorable for tumor progression [89]. Collectively, tumor-derived exosomes negatively modify immune cell function and participate in tumor growth.Fig. 2 Effect of exosomes derived from hypoxic tumor cells on immune cells and angiogenesis Role of hypoxic exosomes in tumor angiogenesis Angiogenesis, the progress of new blood vessels from the pre-existing vessels, is a complex process and a critical factor that promotes the growth and metastasis of several solid tumors [90]. Hypoxia is frequently seen in the tumor microenvironment and up-regulates angiogenesis [91]. This process is highly regulated by various ligands, receptors, and several signaling pathways. Angiogenesis switch on/off is related to the balance between anti and pro-angiogenic factors. A growing body of evidence has highlighted the key role of the miRs cargo of hypoxic exosomes in tumor angiogenesis. A study by Umezu and co-workers demonstrated that miR-135b is abundantly present in hypoxia-resistant multiple myeloma (HR-MM) cells that enhance angiogenesis in human umbilical vein endothelial cells (HUVECs) through targeting HIF-1 in vitro [69]. Hypoxic lung cancer cells secrete exosomes enriched with miR-23a that facilitate the angiogenesis in HUVECs by down-regulating ZO-1 and prolyl hydroxylase proteins. These proteins are involved in tight junction [92]. Hypoxia increased miR-494 molecules in exosomes of non-small cell lung cancer (NSCLC) cells through the HIF-1α-mediated mechanism. These exosomes down-regulated PTEN and activated Akt/eNOS axis in HUVECs, and therefore promoted angiogenesis [93]. Recently, an analysis of exosomes from hypoxic human breast cancer cell line (MDA-MB-231 cells) showed that these exosomes contain many types of angiogenic mRNAs that can promote angiogenesis in HUVECs. Co-culturing of these exosomes with HUVECs could deliver exosomal VEGF-A mRNAs from tumor cells to HUVECs and were translated into protein in HUVECs, therefore induced VEGFR2-dependent angiogenesis [94]. Mao et al. [95] reported that exosomes released from hypoxic esophageal squamous cell carcinoma increased growth, migration, invasion, and tubulogenesis of HUVECs both in vitro and in vivo as compared to exosomes derived from normoxic cells. Under hypoxic conditions, pancreatic tumor cells release exosomes enriched with noncoding RNA UCA1 molecules that promote angiogenesis via miR-96-5p/AMOTL2/ERK1/2 axis both in vitro and in vivo [96]. Exosomes derived from hypoxic glioblastoma cells have been shown to transfer miR-182-5p that can directly inhibit miR-182-5p targets Kruppel-like factor 2 and 4, resulting in the up-regulation of VEGFR, thus increasing tumor angiogenesis. Furthermore, exosomal miR-182-5p can target tight junction-related proteins including occludin, ZO-1, and claudin-5 in ECs which result in promoting migration and metastasis [97]. A study by Matsuura et al. [98] demonstrated that exosomes isolated from human liver cancer cell lines (PLC/PRF/5 and HuH7) increased the angiogenic activity of HUVECs. They showed that these exosomes were enriched with miR-155 responsible for inducing angiogenesis in HUVECs. Exosomes derived from hypoxic papillary thyroid tumor cells including KTC-1 and BCPAP cells promoted the angiogenesis in HUVECs compared with those of normal thyroid follicular cell lines (Nthy-ori-3-1), normoxic BCPAP cells both in vitro and in vivo. In keeping, it was demonstrated that hypoxic exosomes contain high levels of miR-21, which targeted COL4A1 and TGFBI andinduced tubulogenesis and angiogenesis [99]. More recently, Mo et al. [100] found that exosomes derived from hypoxic A549 lung cancer cells contain angiopoietin-like 4 protein that induces angiogenesis in HUVECs. Also, exosomal miR-210 released from hypoxic leukemia cells induced tubulogenesis in ECs [101]. These data show exosomes from hypoxic tumor cells can promote angiogenesis, thus these exosomes may serve as a novel target for cancer treatment. Diagnostic application of hypoxic exosomes Early diagnosis of cancer is the hallmark of cancer therapy that improves the survival rate and quality of a patient’s life [102]. As exosomes released from tumor cells can be distributed to several bio-fluids, thus, a simple liquid-biopsy from plasma, serum, urine, and CSF is a non-invasive way for acquiring detailed information about tumor environment/status [15]. As exosomes originate directly from tumor cells, they may serve as a diagnostic tool for predicting the extent of the physiological and pathological status of tumor cells. Exosomes cargo like proteins and nucleic acids are altered upon the change in the dynamic of parental cells, suggesting a prognostic and diagnostic tool for the treatment of cancer [103]. Analyzing exosomal cargoes (miRs and proteins) gives a chance for scientists to predict the status of a pathological condition like tumor progression. Therefore, as under hypoxia condition tumor cells release more exosomes with distinct cargoes; they may be potentially used as a biomarker for hypoxia tumors. Exosomal biomarker represents superiority against other approaches evaluating hypoxia. Currently, some of the approaches have clinical challenges in estimating hypoxia. For instance, pimonidazole and immunohistochemistry techniques are invasive and necessitate surgical elimination of tumors. Consequently, the application of tumor-derived exosomes from bio-fluids to obtain evidence of hypoxia standing in various cancers could be noteworthy. In this regard, exosomal miRs and protein obtained from bio-fluids have biomarker potential for the diagnosis of different cancers [104, 105]. For example, Matsumura et al. [106] reported that expression of miR-19a in exosomes isolated from the serum of CRC patients was up-regulated, which could be considered as a relapse biomarker of CRC. In the case of hypoxic tumors, confirmed that HIF-1 mRNA molecules are enriched within tumor-derived exosomes that are commonly considered as a typical biomarker for diagnosing cancer development as well as therapy consequences [79]. A study conducted by Kucharzewska et al. [107] demonstrated that exosomes obtained from both Glioblastoma multiform (GBM) cells culture medium and isolated from the GBM patients plasma abundantly contain hypoxia-regulated proteins and mRNAs including PDGFs, Caveolin 1, IL- 8, MMPs, and LOX. The authors conclude that the mRNA and proteome content of these exosomes reflect the hypoxic status of cancer and have biomarker potential for GBM. Also, miRs and metabolites cargo of hypoxic exosome would be useful as a biomarker for diagnosis and prognosis of different cancers such as prostate, colorectal, and pancreatic cancers [108–110]. For example, the expression pattern of exosomal miR-210 from the serum of CRC patients may function as a promising non-invasive biomarker for the diagnosis and prognosis of CRC [108]. During the hypoxic condition, miR-210 is the most extensively and consistently up-regulated miR that commonly shows tumorigenesis properties in different tumors [111]. Similar to hypoxic exosomes from prostate tumor cells (PCa and LNCaP), exosomes obtained from the serum of PCa patients contain a high level of miR-885 and miR-521 [109]. Besides, proteins cargo (VLA-4, TYRP2, HSP90, and HSP70) of exosomes derived from the plasma of melanoma patients are significantly increased in comparison with healthy persons [112]. VLA-4 and TYRP2 are up-regulated under the hypoxic condition and their high expression in exosomes correlates with stage 3 melanoma [113, 114]. Previous studies have shown that HSP90 and HSP70 are hypoxic related proteins and play roles in hypoxic condition [115, 116]. In this regard, exosomal proteins have diagnostic and prognostic value for the melanoma tumor development and hypoxic status. Therefore, hypoxic exosomes may be a useful tool for predicting the hypoxic status of solid tumors, however, it seems that this evidence is not sufficient and further scrutiny is essential to examine and confirm the potential application of hypoxic exosomes to quantify the degree of hypoxia to detect stages of tumor development. Possible therapeutic application of exosomes Exosomes can reach target cells and alter the function, fate, and morphology through different signaling pathways. As mentioned, tumor cells under hypoxic conditions produce more exosomes, promoting tumorigenesis. Thus, it seems that targeting exosomes formation and secretion particularly from the hypoxic tumor may provide us with a tool that reduces tumorigenesis. Recent findings have shown that it is possible to inhibit the exosomes biogenesis and secretion from different cells. For example, Manumycin A and GW4869 have been shown to inhibit exosome biogenesis and release from cells [117]. Datta et al. [118] reported that Manumycin A inhibited exosomes biogenesis and secretion from aggressive prostate cells mainly by suppression of Ras/Raf/ERK1/2 signaling and hnRNP H1. They concluded that Manumycin A is a potential drug candidate to inhibit exosome biogenesis and secretion. Suppression of Rab27a, a protein involved in exosomes secretion, has been shown to inhibit exosome-dependent and -independent tumor cells growth [119]. Inhibition of Rab proteins involved in intracellular trafficking of exosomes/MVB may inhibit exosomes biogenesis and release, thus they may be a target to inhibit exosome biogenesis. For example, Rab5a has been involved in the early step of exosomes biogenesis, while Rab11, Rab27a, and Rab35 regulate the MVBs-plasma membrane fusion and exosomes secretion. Moreover, inhibition of sphingomyelinase, an enzyme catalyzes the formation of ceramide from sphingomyelin, may lessen exosomes biogenesis and loading, thus prevents tumor growth [120]. In human prostate cancer (PC3) cells, it was shown that Imipramine profoundly inhibited the biogenesis of both microvesicles and exosomes [121]. A fascinating approach has been proposed by Marleau and colleagues based on the effective elimination of blood exosomes of breast cancer patients by extracorporeal hemofiltration associated with affinity agents like exosome-trapping antibodies and lectins. This approach was proposed to trap particles < 200 nm from the whole circulatory system [122]. Considering the existence of numerous experiments on exosomes inhibition, there are challenges regarding analyzing and conclusions of findings, because as various methods are used to isolate and characterize exosomes. Moreover, some researchers did not include ISEV guidelines regarding the exosomes confirmation and validation, as exosome-based studies had been performed before the 2014 and 2018 declaration of ISEV guidelines about exosome-based studies [30, 123]. Besides, it is vital to discover the non-toxic doses of the drugs for target cells to confirm that any decrease in exosomes secretion resulting from exosomes inhibition not from cell death. The majority of these experiments were pre-clinical performed, thus, clinical trials are essential for the approval. Furthermore, the non-targeting effects of these drugs on exosomes biogenesis from normal cells remain an important concern. At least, in the field of cancer, key studies must still be necessary to investigate their effects on exosomes production from both healthy and tumor cells and to progress methods to specifically deliver drugs into tumor cells. Another approach that exosomes can be used as a therapeutic agent is the drug delivery potential of them. According to previous studies, exosomes can be used as a drug delivery system in two ways: (I); direct loading by which therapeutic agents directly sorted into exosomes; and (II); indirect loading where source cells co-cultured with therapeutic agents or manipulated genetically to produce optional exosomes. In this regard, different approaches for producing optional exosomes have been examined, which comprise: incubating exosomes with the agents, electroporation, sonication, sensitive fusogenic peptide, and cationic lipid, liposome, and exosome-coated metal–organic nanoparticle [124, 125]. An example of the direct method, Zhuang et al. [126] encapsulated curcumin into tumor cell-derived exosomes. Then, these exosomes successfully delivered these exosomes to microglia cells through an intranasal way in a brain inflammatory model of mice. Also, the authors successfully inserted a Stat3 inhibitor into the same exosomes. They demonstrate that this method could provide a noninvasive and new therapeutic approach for the treatment of brain diseases. Besides drugs, siRNAs can also be loaded into the hydrophilic core of exosomes in the pharmaceutically active form [127, 128]. In this regard, Alvarez-Erviti et al. [129], for example, successfully loaded siRNAs into exosomes purified from dendritic cells and delivered those exosomes to the mouse brain. An example of an indirect loading method, Pascucci et al. [130] co-cultured MSCs with paclitaxel (PTX) and then isolated exosomes from the supernatant. In keeping, they found that PTX was sorted into exosomes and these exosomes exhibited strong anti-tumor activity in vitro. Interestingly, exosomes from hypoxic MDA-MB-231 human breast cancer cells loaded with anti-cancer drug Olaparib exhibited better uptake rate when co-cultured with hypoxic cancer cells [131]. Collectively, exosomes may serve as a new avenue to overcome cancer, however, translation of pre-clinical results into the clinic needs more experiments regarding exosomes biology and bio-applications in disease models. Conclusion Hypoxia increases exosome biogenesis and secretion in tumor cells. Moreover, it can alter exosomes cargo. Exosomes released from tumor cells play a pivotal role in promoting growth, metastasis, and resistance of hypoxic tumors. Furthermore, exosomes from hypoxic tumors have been suggested to be a promising non-invasive biomarker for cancer diagnosis through analyzing their components such as proteins and miRs. Inhibition of exosomes biogenesis and secretion may help to reduce tumorigenesis. Exosomes can be used as a drug delivery system for the treatment of cancer. However, despite many experiments, translation of the preclinical findings into the clinic requires additional examinations in this field. Therefore, further scrutiny is essential for a better understanding of the mechanisms behind exosome loading and production under hypoxic conditions, which could be useful in targeting exosomes biogenesis and prevent tumorigenesis. Abbreviations ABsApoptotic bodies AMPKAMP-activated protein kinase CAFsCancer-associated fibroblasts CMAChaperone-mediated autophagy CMLChronic myeloid leukemia d-GalN/LPSD-galactosamine and Lipopolysaccharide GBMGlioblastoma multiform ECMExtracellular matrix ECsEndothelial cells EMTEpithelial-to-mesenchymal transition ESCRTEndosomal sorting complex required for transport EVsExtracellular vesicles HIFsHypoxia-inducible factors HREHypoxia-responsive element HR-MMHypoxia-resistant multiple myeloma HUVECsHuman umbilical vein endothelial cells ILVsIntraluminal vesicles ISEVInternational Society for Extracellular Vesicles Protein type 2A LOXProtein-lysine 6-oxidase MAPKMitogen-activated protein kinases MHCMajor histocompatibility complex MMPsMatrix metalloproteinase MSCsMesenchymal stem cells MSDCsMyeloid-derived suppressor cells mTORMammalian target of rapamycin MVMicrovesicles MVBsMultivesicular bodies nSMase2Sphingomyelinase 2 NSCLCNon-small cell lung cancer NOXNADPH oxidase NPCNasopharyngeal carcinoma PI3KPhosphatidylinositol 3-kinases PHDProlylhydroxylase PKM2Pyruvate kinase 2 PLPProteolipid proteins PMPlasma membrane PTXPaclitaxel ROCKRHO-associated protein kinase ROSReactive oxygen species SNAREsSoluble NSF attachment protein receptors TLRToll-like receptors VHLVon Hippel-Lindau Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements Not applicable. Authors’ contributions RJ and JR conceived the ideas. JR, MA and MH collected data. RR and JR designed and reviewed the manuscript. All authors reviewed the manuscript. All authors read and approved the final manuscript. Funding Not applicable. Availability of data and materials The primary data for this study is available from the authors on direct request. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. ==== Refs References 1. Deep G, Panigrahi GK. Hypoxia-induced signaling promotes prostate cancer progression: exosomes role as messenger of hypoxic response in tumor microenvironment. Critical Reviews™ in Oncogenesis 2015, 20. 2. Al Tameemi W Dale TP Al-Jumaily RMK Forsyth NR Hypoxia-modified cancer cell metabolism Front Cell Dev Biol 2019 7 4 10.3389/fcell.2019.00004 30761299 3. McKeown S Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response Br J Radiol 2014 87 20130676 10.1259/bjr.20130676 24588669 4. Tomes L Emberley E Niu Y Troup S Pastorek J Strange K Harris A Watson PH Necrosis and hypoxia in invasive breast carcinoma Breast Cancer Res Treat 2003 81 61 69 10.1023/A:1025476722493 14531498 5. Balkwill FR, Capasso M, Hagemann T: The tumor microenvironment at a glance. The Company of Biologists Ltd; 2012. 6. Folkman J: Role of angiogenesis in tumor growth and metastasis. In Seminars in oncology. Elsevier; 2002: 15–18. 7. Semenza GL Hypoxia-inducible factors in physiology and medicine Cell 2012 148 399 408 10.1016/j.cell.2012.01.021 22304911 8. Harada H Inoue M Itasaka S Hirota K Morinibu A Shinomiya K Zeng L Ou G Zhu Y Yoshimura M Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels Nature communications 2012 3 1 12 10.1038/ncomms1786 9. Ivan M Kondo K Yang H Kim W Valiando J Ohh M Salic A Asara JM Lane WS Kaelin WG Jr HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 2001 292 464 468 10.1126/science.1059817 11292862 10. Tukmechi A Rezaee J Nejati V Sheikhzadeh N Effect of acute and chronic toxicity of paraquat on immune system and growth performance in rainbow trout, O ncorhynchus mykiss Aquacult Res 2014 45 1737 1743 11. Semenza GL Targeting HIF-1 for cancer therapy Nat Rev Cancer 2003 3 721 732 10.1038/nrc1187 13130303 12. Mitani T Harada N Nakano Y Inui H Yamaji R Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling J Biol Chem 2012 287 33594 33606 10.1074/jbc.M112.388298 22865883 13. Harris AL Hypoxia—a key regulatory factor in tumour growth Nat Rev Cancer 2002 2 38 47 10.1038/nrc704 11902584 14. Zhang W Zhou X Yao Q Liu Y Zhang H Dong Z HIF-1-mediated production of exosomes during hypoxia is protective in renal tubular cells American Journal of Physiology-Renal Physiology 2017 313 F906 F913 10.1152/ajprenal.00178.2017 28679592 15. Kowal J Tkach M Théry C Biogenesis and secretion of exosomes Curr Opin Cell Biol 2014 29 116 125 10.1016/j.ceb.2014.05.004 24959705 16. Jabbari N Akbariazar E Feqhhi M Rahbarghazi R Rezaie J Breast cancer-derived exosomes: tumor progression and therapeutic agents J Cell Physiol 2020 10.1002/jcp.29668 32216070 17. Lu X Kang Y Hypoxia and hypoxia-inducible factors: master regulators of metastasis Clin Cancer Res 2010 16 5928 5935 10.1158/1078-0432.CCR-10-1360 20962028 18. Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. In: Seminars in cancer biology. Elsevier; 2012, p. 342–349. 19. Park JE Tan HS Datta A Lai RC Zhang H Meng W Lim SK Sze SK Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes Mol Cell Proteomics 2010 9 1085 1099 10.1074/mcp.M900381-MCP200 20124223 20. Giraldo NA Sanchez-Salas R Peske JD Vano Y Becht E Petitprez F Validire P Ingels A Cathelineau X Fridman WH The clinical role of the TME in solid cancer Br J Cancer 2019 120 45 53 10.1038/s41416-018-0327-z 30413828 21. Yuan Y Jiang Y-C Sun C-K Chen Q-M Role of the tumor microenvironment in tumor progression and the clinical applications Oncol Rep 2016 35 2499 2515 10.3892/or.2016.4660 26986034 22. Khaksar M Sayyari M Rezaie J Pouyafar A Montazersaheb S Rahbarghazi R High glucose condition limited the angiogenic/cardiogenic capacity of murine cardiac progenitor cells in in vitro and in vivo milieu Cell Biochem Funct 2018 36 346 356 10.1002/cbf.3354 30051492 23. Petrova V Annicchiarico-Petruzzelli M Melino G Amelio I The hypoxic tumour microenvironment Oncogenesis 2018 7 1 13 10.1038/s41389-017-0011-9 29367650 24. Lucero R Zappulli V Sammarco A Murillo OD Cheah PS Srinivasan S Tai E Ting DT Wei Z Roth ME Glioma-derived miRNA-containing extracellular vesicles induce angiogenesis by reprogramming brain endothelial cells Cell Rep 2020 30 2065–2074 e2064 25. Varricchi G Loffredo S Galdiero MR Marone G Cristinziano L Granata F Marone G Innate effector cells in angiogenesis and lymphangiogenesis Curr Opin Immunol 2018 53 152 160 10.1016/j.coi.2018.05.002 29778674 26. Xie F Zhou X Fang M Li H Su P Tu Y Zhang L Zhou F Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy Adv Sci 2019 6 1901779 10.1002/advs.201901779 27. Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. In: Seminars in immunology. Elsevier; 2018, p. 69–79. 28. Jarosz-Biej M Smolarczyk R Cichoń T Kułach N Tumor microenvironment as A “Game Changer” in cancer radiotherapy Int J Mol Sci 2019 20 3212 10.3390/ijms20133212 29. Peng J Yang Q Shi K Xiao Y Wei X Qian Z Intratumoral fate of functional nanoparticles in response to microenvironment factor: Implications on cancer diagnosis and therapy Adv Drug Deliv Rev 2019 143 37 67 10.1016/j.addr.2019.06.007 31276708 30. Théry C Witwer KW Aikawa E Alcaraz MJ Anderson JD Andriantsitohaina R Antoniou A Arab T Archer F Atkin-Smith GK Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines Journal of extracellular vesicles 2018 7 1535750 10.1080/20013078.2018.1535750 30637094 31. Record M Silvente-Poirot S Poirot M Wakelam MJ Extracellular vesicles: lipids as key components of their biogenesis and functions J Lipid Res 2018 59 1316 1324 10.1194/jlr.E086173 29764923 32. Théry C Zitvogel L Amigorena S Exosomes: composition, biogenesis and function Nat Rev Immunol 2002 2 569 579 10.1038/nri855 12154376 33. McKelvey KJ Powell KL Ashton AW Morris JM McCracken SA Exosomes: mechanisms of uptake J Circulating Biomarkers 2015 4 7 10.5772/61186 34. Hassanpour M Rezaie J Nouri M Panahi Y The role of extracellular vesicles in COVID-19 virus infection Infect Genet Evol 2020 10.1016/j.meegid.2020.104422 32544615 35. Shen B Fang Y Wu N Gould SJ Biogenesis of the posterior pole is mediated by the exosome/microvesicle protein-sorting pathway J Biol Chem 2011 286 44162 44176 10.1074/jbc.M111.274803 21865156 36. Yang J-M Gould SJ The cis-acting signals that target proteins to exosomes and microvesicles 2013 London Portland Press Ltd. 37. Mulcahy LA Pink RC Carter DRF Routes and mechanisms of extracellular vesicle uptake J Extracellular Vesicles 2014 3 24641 10.3402/jev.v3.24641 38. Morelli AE Larregina AT Shufesky WJ Sullivan ML Stolz DB Papworth GD Zahorchak AF Logar AJ Wang Z Watkins SC Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells Blood 2004 104 3257 3266 10.1182/blood-2004-03-0824 15284116 39. Hassanpour M Rahbarghazi R Nouri M Aghamohammadzadeh N Safaei N Ahmadi M Role of autophagy in atherosclerosis: foe or friend? J Inflamm 2019 16 8 10.1186/s12950-019-0212-4 40. Wang T Gilkes DM Takano N Xiang L Luo W Bishop CJ Chaturvedi P Green JJ Semenza GL Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis Proc Natl Acad Sci USA 2014 111 E3234 3242 10.1073/pnas.1410041111 24938788 41. King HW Michael MZ Gleadle JM Hypoxic enhancement of exosome release by breast cancer cells BMC Cancer 2012 12 421 10.1186/1471-2407-12-421 22998595 42. Kucharzewska P Christianson HC Welch JE Svensson KJ Fredlund E Ringnér M Mörgelin M Bourseau-Guilmain E Bengzon J Belting M Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development Proc Natl Acad Sci USA 2013 110 7312 7317 10.1073/pnas.1220998110 23589885 43. Liu W Li L Rong Y Qian D Chen J Zhou Z Luo Y Jiang D Cheng L Zhao S Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126 Acta Biomater 2020 103 196 212 10.1016/j.actbio.2019.12.020 31857259 44. Liu W Rong Y Wang J Zhou Z Ge X Ji C Jiang D Gong F Li L Chen J Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization J Neuroinflammation 2020 17 1 22 10.1186/s12974-019-1655-5 31900165 45. Semenza GL Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 2010 29 625 634 10.1038/onc.2009.441 19946328 46. Luo W Hu H Chang R Zhong J Knabel M O'Meally R Cole RN Pandey A Semenza GL Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 2011 145 732 744 10.1016/j.cell.2011.03.054 21620138 47. Vaupel P Harrison L Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response Oncologist 2004 9 4 9 10.1634/theoncologist.9-90005-4 15591417 48. Wei Y Wang D Jin F Bian Z Li L Liang H Li M Shi L Pan C Zhu D Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23 Nat Commun 2017 8 1 12 10.1038/s41467-016-0009-6 28232747 49. Parolini I Federici C Raggi C Lugini L Palleschi S De Milito A Coscia C Iessi E Logozzi M Molinari A Microenvironmental pH is a key factor for exosome traffic in tumor cells J Biol Chem 2009 284 34211 34222 10.1074/jbc.M109.041152 19801663 50. Ban J-J Lee M Im W Kim M Low pH increases the yield of exosome isolation Biochem Biophys Res Commun 2015 461 76 79 10.1016/j.bbrc.2015.03.172 25849885 51. Jordens I Marsman M Kuijl C Neefjes J Rab proteins, connecting transport and vesicle fusion Traffic 2005 6 1070 1077 10.1111/j.1600-0854.2005.00336.x 16262719 52. Stenmark H Olkkonen VM The rab gtpase family Genome Biol 2001 2 reviews3007 3001 53. Dorayappan KDP Wanner R Wallbillich JJ Saini U Zingarelli R Suarez AA Cohn DE Selvendiran K Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins Oncogene 2018 37 3806 3821 10.1038/s41388-018-0189-0 29636548 54. Panigrahi GK Praharaj PP Peak TC Long J Singh R Rhim JS Abd Elmageed ZY Deep G Hypoxia-induced exosome secretion promotes survival of African-American and Caucasian prostate cancer cells Sci Rep 2018 8 3853 10.1038/s41598-018-22068-4 29497081 55. Wang Z Jin N Ganguli S Swartz DR Li L Rhoades RA Rho-Kinase activation is involved in hypoxia-induced pulmonary vasoconstriction Am J Respir Cell Mol Biol 2001 25 628 635 10.1165/ajrcmb.25.5.4461 11713106 56. Li B Antonyak MA Zhang J Cerione RA RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells Oncogene 2012 31 4740 4749 10.1038/onc.2011.636 22266864 57. Yang JCS Lin MW Rau CS Jeng SF Lu TH Wu YC Chen YC Tzeng SL Wu CJ Hsieh CH Altered exosomal protein expression in the serum of NF-κB knockout mice following skeletal muscle ischemia-reperfusion injury J Biomed Sci 2015 22 40 10.1186/s12929-015-0147-x 26059504 58. Hedlund M Nagaeva O Kargl D Baranov V Mincheva-Nilsson L Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells PLoS ONE 2011 6 e16899 10.1371/journal.pone.0016899 21364924 59. Kim B Boo K Lee JS Kim KI Kim WH Cho H-J Park Y-B Kim H-S Baek SH Identification of the KAI1 metastasis suppressor gene as a hypoxia target gene Biochem Biophys Res Commun 2010 393 179 184 10.1016/j.bbrc.2010.01.118 20123085 60. Chairoungdua A Smith DL Pochard P Hull M Caplan MJ Exosome release of β-catenin: a novel mechanism that antagonizes Wnt signaling J Cell Biol 2010 190 1079 1091 10.1083/jcb.201002049 20837771 61. Hervera A De Virgiliis F Palmisano I Zhou L Tantardini E Kong G Hutson T Danzi MC Perry RBT Santos CX Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons Nat Cell Biol 2018 20 307 319 10.1038/s41556-018-0039-x 29434374 62. Zhang W Zhou Q Wei Y Da M Zhang C Zhong J Liu J Shen J The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer Int J Clin Exp Pathol 2019 12 2474 31934074 63. Jung KO Youn H Lee C-H Kang KW Chung J-K Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells Oncotarget 2017 8 9899 10.18632/oncotarget.14247 28038441 64. Ding L Zhao L Chen W Liu T Li Z Li X miR-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell Int J Clin Exp Med 2015 8 2299 2307 25932166 65. Huang X Ding L Bennewith KL Tong RT Welford SM Ang KK Story M Le Q-T Giaccia AJ Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation Mol Cell 2009 35 856 867 10.1016/j.molcel.2009.09.006 19782034 66. Huang Z Yang M Li Y Yang F Feng Y Exosomes derived from hypoxic colorectal cancer cells transfer Wnt4 to normoxic cells to elicit a prometastatic phenotype Int J Biol Sci 2018 14 2094 10.7150/ijbs.28288 30585272 67. Ramteke A Ting H Agarwal C Mateen S Somasagara R Hussain A Graner M Frederick B Agarwal R Deep G Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules Mol Carcinog 2015 54 554 565 10.1002/mc.22124 24347249 68. Kore RA Edmondson JL Jenkins SV Jamshidi-Parsian A Dings RPM Reyna NS Griffin RJ Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells Biochem Biophys Rep 2018 14 104 113 29872742 69. Umezu T Tadokoro H Azuma K Yoshizawa S Ohyashiki K Ohyashiki JH Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1 Blood 2014 124 3748 3757 10.1182/blood-2014-05-576116 25320245 70. Chiang AC Massagué J Molecular basis of metastasis N Engl J Med 2008 359 2814 2823 10.1056/NEJMra0805239 19109576 71. Chowdhury R Webber JP Gurney M Mason MD Tabi Z Clayton A Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts Oncotarget 2015 6 715 10.18632/oncotarget.2711 25596732 72. Huber MA Kraut N Beug H Molecular requirements for epithelial–mesenchymal transition during tumor progression Curr Opin Cell Biol 2005 17 548 558 10.1016/j.ceb.2005.08.001 16098727 73. Tan EJ Olsson A-K Moustakas A Reprogramming during epithelial to mesenchymal transition under the control of TGFβ Cell Adhesion Migration 2015 9 233 246 10.4161/19336918.2014.983794 25482613 74. Peng Z Wang C-X Fang E-H Wang G-B Tong Q Role of epithelial-mesenchymal transition in gastric cancer initiation and progression World J Gastroenterol 2014 20 5403 5410 10.3748/wjg.v20.i18.5403 24833870 75. Onder TT Gupta PB Mani SA Yang J Lander ES Weinberg RA Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways Can Res 2008 68 3645 10.1158/0008-5472.CAN-07-2938 76. Xue M Chen W Xiang A Wang R Chen H Pan J Pang H An H Wang X Hou H Li X Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1 Mol Cancer 2017 16 143 10.1186/s12943-017-0714-8 28841829 77. Li L Li C Wang S Wang Z Jiang J Wang W Li X Chen J Liu K Li C Zhu G Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype Can Res 2016 76 1770 10.1158/0008-5472.CAN-15-1625 78. Takahashi K Yan IK Haga H Patel T Modulation of hypoxia-signaling pathways by extracellular linc-RoR J Cell Sci 2014 127 1585 10.1242/jcs.141069 24463816 79. Aga M Bentz GL Raffa S Torrisi MR Kondo S Wakisaka N Yoshizaki T Pagano JS Shackelford J Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes Oncogene 2014 33 4613 4622 10.1038/onc.2014.66 24662828 80. Wang Y Yi J Chen X Zhang Y Xu M Yang Z The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10 Oncol Lett 2016 11 1527 1530 10.3892/ol.2015.4044 26893774 81. Sceneay J Parker BS Smyth MJ Möller A Hypoxia-driven immunosuppression contributes to the pre-metastatic niche Oncoimmunology 2013 2 e22355 e22355 10.4161/onci.22355 23482904 82. Filipazzi P Bürdek M Villa A Rivoltini L Huber V Recent advances on the role of tumor exosomes in immunosuppression and disease progression Semin Cancer Biol 2012 22 342 349 10.1016/j.semcancer.2012.02.005 22369922 83. Liu C Yu S Zinn K Wang J Zhang L Jia Y Kappes JC Barnes S Kimberly RP Grizzle WE Zhang H-G Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function J Immunol 2006 176 1375 1385 10.4049/jimmunol.176.3.1375 16424164 84. Ye SB, Zhang H, Cai TT, Liu YN, Ni JJ, He J, Peng JY, Chen QY, Mo HY, Jun-Cui, et al: Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. J Pathol 2016, 240:329–340. 85. Wen SW Sceneay J Lima LG Wong CSF Becker M Krumeich S Lobb RJ Castillo V Wong KN Ellis S The biodistribution and immune suppressive effects of breast cancer-derived exosomes Can Res 2016 76 6816 10.1158/0008-5472.CAN-16-0868 86. Fabbri M Paone A Calore F Galli R Gaudio E Santhanam R Lovat F Fadda P Mao C Nuovo GJ MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response Proc Natl Acad Sci 2012 109 E2110 E2116 10.1073/pnas.1209414109 22753494 87. Theodoraki M-N Hoffmann TK Jackson EK Whiteside TL Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence Clin Exp Immunol 2018 194 67 78 10.1111/cei.13157 30229863 88. Liu Y Xiang X Zhuang X Zhang S Liu C Cheng Z Michalek S Grizzle W Zhang H-G Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells The American journal of pathology 2010 176 2490 2499 10.2353/ajpath.2010.090777 20348242 89. Chen X Ying X Wang X Wu X Zhu Q Wang X Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization Oncol Rep 2017 38 522 528 10.3892/or.2017.5697 28586039 90. Hasina R Lingen MW Angiogenesis in oral cancer J Dent Educ 2001 65 1282 1290 10.1002/j.0022-0337.2001.65.11.tb03489.x 11765876 91. Muz B de la Puente P Azab F Azab AK The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy Hypoxia 2015 3 83 10.2147/HP.S93413 27774485 92. Hsu YL Hung JY Chang WA Lin YS Pan YC Tsai PH Wu CY Kuo PL Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1 Oncogene 2017 36 4929 4942 10.1038/onc.2017.105 28436951 93. Mao G Liu Y Fang X Liu Y Fang L Lin L Liu X Wang N Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer Angiogenesis 2015 18 373 382 10.1007/s10456-015-9474-5 26040900 94. Zhang P, Lim SB, Jiang K, Chew TW, Low BC, Lim CT. Cancer exosomes harbor diverse hypoxia-targeted mRNAs and contribute toward tumor angiogenesis. bioRxiv 2020. 95. Mao Y Wang Y Dong L Zhang Y Zhang Y Wang C Zhang Q Yang S Cao L Zhang X Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells J Exp Clin Cancer Res 2019 38 389 10.1186/s13046-019-1384-8 31488217 96. Guo Z Wang X Yang Y Chen W Zhang K Teng B Huang C Zhao Q Qiu Z Hypoxic tumor-derived exosomal long noncoding RNA UCA1 promotes angiogenesis via miR-96-5p/AMOTL2 in pancreatic cancer Mol Ther Nucleic Acids 2020 22 179 195 10.1016/j.omtn.2020.08.021 32942233 97. Li J Yuan H Xu H Zhao H Xiong N Hypoxic cancer-secreted exosomal miR-182-5p promotes glioblastoma angiogenesis by targeting Kruppel-like factor 2 and 4 Mol Cancer Res 2020 18 1218 1231 10.1158/1541-7786.MCR-19-0725 32366676 98. Matsuura Y Wada H Eguchi H Gotoh K Kobayashi S Kinoshita M Kubo M Hayashi K Iwagami Y Yamada D Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells Dig Dis Sci 2019 64 792 802 10.1007/s10620-018-5380-1 30465177 99. Wu F Li F Lin X Xu F Cui R-R Zhong J-Y Zhu T Shan S-K Liao X-B Yuan L-Q Exosomes increased angiogenesis in papillary thyroid cancer microenvironment Endocr Relat Cancer 2019 26 525 538 10.1530/ERC-19-0008 30870812 100. Mo F Xu Y Zhang J Zhu L Wang C Chu X Pan Y Bai Y Shao C Zhang J Effects of hypoxia and radiation-induced exosomes on migration of lung cancer cells and angiogenesis of umbilical vein endothelial cells Radiat Res 2020 10.1667/RR15555.1/436363 32352864 101. Tadokoro H Umezu T Ohyashiki K Hirano T Ohyashiki JH Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells J Biol Chem 2013 288 34343 34351 10.1074/jbc.M113.480822 24133215 102. Schiffman JD Fisher PG Gibbs P Early detection of cancer: past, present, and future Am Soc Clin Oncol Educ Book 2015 35 57 65 10.14694/EdBook_AM.2015.35.57 103. Duijvesz D Luider T Bangma CH Jenster G Exosomes as biomarker treasure chests for prostate cancer Eur Urol 2011 59 823 831 10.1016/j.eururo.2010.12.031 21196075 104. Hildonen S Skarpen E Halvorsen TG Reubsaet L Isolation and mass spectrometry analysis of urinary extraexosomal proteins Sci Rep 2016 6 36331 10.1038/srep36331 27805059 105. Duijvesz D Burnum-Johnson KE Gritsenko MA Hoogland AM Vredenbregt-van den Berg MS Willemsen R Luider T Paša-Tolić L Jenster G Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer PLoS ONE 2013 8 e82589 10.1371/journal.pone.0082589 24391718 106. Matsumura T Sugimachi K Iinuma H Takahashi Y Kurashige J Sawada G Ueda M Uchi R Ueo H Takano Y Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer Br J Cancer 2015 113 275 10.1038/bjc.2015.201 26057451 107. Kucharzewska P Christianson HC Welch JE Svensson KJ Fredlund E Ringnér M Mörgelin M Bourseau-Guilmain E Bengzon J Belting M Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development Proc Natl Acad Sci 2013 110 7312 7317 10.1073/pnas.1220998110 23589885 108. Wang W Qu A Liu W Liu Y Zheng G Du L Zhang X Yang Y Wang C Chen X Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer Eur J Cancer Care 2017 26 e12448 10.1111/ecc.12448 109. Panigrahi GK Ramteke A Birks D Ali HEA Venkataraman S Agarwal C Vibhakar R Miller LD Agarwal R Elmageed ZYA Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer Oncotarget 2018 9 13894 10.18632/oncotarget.24532 29568403 110. Altadill T Campoy I Lanau L Gill K Rigau M Gil-Moreno A Reventos J Byers S Colas E Cheema AK Enabling metabolomics based biomarker discovery studies using molecular phenotyping of exosome-like vesicles PLoS ONE 2016 11 e0151339 10.1371/journal.pone.0151339 26974972 111. Dang K Myers KA The role of hypoxia-induced miR-210 in cancer progression Int J Mol Sci 2015 16 6353 6372 10.3390/ijms16036353 25809609 112. Peinado H Alečković M Lavotshkin S Matei I Costa-Silva B Moreno-Bueno G Hergueta-Redondo M Williams C García-Santos G Ghajar CM Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET Nat Med 2012 18 883 10.1038/nm.2753 22635005 113. Zhao XP Wang M Song Y Song K Yan TL Wang L Liu K Shang ZJ Membrane microvesicles as mediators for melanoma-fibroblasts communication: roles of the VCAM-1/VLA-4 axis and the ERK1/2 signal pathway Cancer Lett 2015 360 125 133 10.1016/j.canlet.2015.01.032 25661735 114. Zbytek B Peacock DL Seagroves TN Slominski A Putative role of HIF transcriptional activity in melanocytes and melanoma biology Dermato Endocrinol 2013 5 239 251 10.4161/derm.22678 115. Zhou J Schmid T Frank R Brüne B PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation J Biol Chem 2004 279 13506 13513 10.1074/jbc.M310164200 14726529 116. Jain K Suryakumar G Ganju L Singh SB Differential hypoxic tolerance is mediated by activation of heat shock response and nitric oxide pathway Cell Stress Chaperones 2014 19 801 812 10.1007/s12192-014-0504-9 24590457 117. Zhou X Zhang W Yao Q Zhang H Dong G Zhang M Liu Y Chen J-K Dong Z Exosome production and its regulation of EGFR during wound healing in renal tubular cells Am J Physiol Renal Physiol 2017 312 F963 F970 10.1152/ajprenal.00078.2017 28356285 118. Datta A Kim H Lal M McGee L Johnson A Moustafa AA Jones JC Mondal D Ferrer M Abdel-Mageed AB Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells Cancer Lett 2017 408 73 81 10.1016/j.canlet.2017.08.020 28844715 119. Bobrie A Krumeich S Reyal F Recchi C Moita LF Seabra MC Ostrowski M Théry C Rab27a supports exosome-dependent and-independent mechanisms that modify the tumor microenvironment and can promote tumor progression Can Res 2012 72 4920 4930 10.1158/0008-5472.CAN-12-0925 120. Trajkovic K Hsu C Chiantia S Rajendran L Wenzel D Wieland F Schwille P Brügger B Simons M Ceramide triggers budding of exosome vesicles into multivesicular endosomes Science 2008 319 1244 1247 10.1126/science.1153124 18309083 121. Kosgodage US Trindade RP Thompson PR Inal JM Lange S Chloramidine/bisindolylmaleimide-I-mediated inhibition of exosome and microvesicle release and enhanced efficacy of cancer chemotherapy Int J Mol Sci 2017 18 1007 10.3390/ijms18051007 122. Marleau AM Chen C-S Joyce JA Tullis RH Exosome removal as a therapeutic adjuvant in cancer J Transl Med 2012 10 134 10.1186/1479-5876-10-134 22738135 123. Lötvall J Hill AF Hochberg F Buzás EI Di Vizio D Gardiner C Gho YS Kurochkin IV Mathivanan S Quesenberry P Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles 2014 Milton Taylor & Francis 124. Bunggulawa EJ Wang W Yin T Wang N Durkan C Wang Y Wang G Recent advancements in the use of exosomes as drug delivery systems J Nanobiotechnol 2018 16 1 13 10.1186/s12951-018-0403-9 125. Johnsen KB Gudbergsson JM Skov MN Pilgaard L Moos T Duroux M A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy Biochimica et Biophysica Acta (BBA) Reviews Cancer 2014 1846 75 87 10.1016/j.bbcan.2014.04.005 126. Zhuang X Xiang X Grizzle W Sun D Zhang S Axtell RC Ju S Mu J Zhang L Steinman L Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain Mol Ther 2011 19 1769 1779 10.1038/mt.2011.164 21915101 127. Aryani A Denecke B Exosomes as a nanodelivery system: a key to the future of neuromedicine? Mol Neurobiol 2016 53 818 834 10.1007/s12035-014-9054-5 25502465 128. Jiang X-C Gao J-Q Exosomes as novel bio-carriers for gene and drug delivery Int J Pharm 2017 521 167 175 10.1016/j.ijpharm.2017.02.038 28216464 129. Alvarez-Erviti L Seow Y Yin H Betts C Lakhal S Wood MJA Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 2011 29 341 345 10.1038/nbt.1807 21423189 130. Pascucci L Coccè V Bonomi A Ami D Ceccarelli P Ciusani E Viganò L Locatelli A Sisto F Doglia SM Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery J Control Release 2014 192 262 270 10.1016/j.jconrel.2014.07.042 25084218 131. Jung KO Jo H Yu JH Gambhir SS Pratx G Development and MPI tracking of novel hypoxia-targeted theranostic exosomes Biomaterials 2018 177 139 148 10.1016/j.biomaterials.2018.05.048 29890363 132. Chen X Zhou J Li X Wang X Lin Y Wang X Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype Cancer Lett 2018 435 80 91 10.1016/j.canlet.2018.08.001 30098399 133. Mace TA Collins AL Wojcik SE Croce CM Lesinski GB Bloomston M Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells J Surg Res 2013 184 855 860 10.1016/j.jss.2013.04.061 23726431 134. Umezu T Tadokoro H Azuma K Yoshizawa S Ohyashiki K Ohyashiki JH Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1 Blood J Am Soc Hematol 2014 124 3748 3757 135. Schlaepfer IR Nambiar DK Ramteke A Kumar R Dhar D Agarwal C Bergman B Graner M Maroni P Singh RP Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation Oncotarget 2015 6 22836 10.18632/oncotarget.4479 26087400 136. Panigrahi GK Praharaj PP Peak TC Long J Singh R Rhim JS Elmageed ZYA Deep G Hypoxia-induced exosome secretion promotes survival of African-American and Caucasian prostate cancer cells Scientific reports 2018 8 1 13 10.1038/s41598-017-17765-5 29311619 137. Huang Z Feng Y Exosomes derived from hypoxic colorectal cancer cells promote angiogenesis through Wnt4-induced β-catenin signaling in endothelial cells Oncol Res Featuring Preclin Clin Cancer Therapeutics 2017 25 651 661 10.3727/096504016X14752792816791 138. Svensson KJ Kucharzewska P Christianson HC Sköld S Löfstedt T Johansson MC Mörgelin M Bengzon J Ruf W Belting M Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2–mediated heparin-binding EGF signaling in endothelial cells Proc Natl Acad Sci 2011 108 13147 13152 10.1073/pnas.1104261108 21788507 139. Horie K Kawakami K Fujita Y Sugaya M Kameyama K Mizutani K Deguchi T Ito M Exosomes expressing carbonic anhydrase 9 promote angiogenesis Biochem Biophys Res Commun 2017 492 356 361 10.1016/j.bbrc.2017.08.107 28851650 140. Shan Y You B Shi S Shi W Zhang Z Zhang Q Gu M Chen J Bao L Liu D Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases Cell Death Dis 2018 9 1 13 10.1038/s41419-017-0012-9 29298988 141. Ye SB Zhang H Cai TT Liu YN Ni JJ He J Peng JY Chen QY Mo HY Zhang XS Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma J Pathol 2016 240 329 340 10.1002/path.4781 27538493 142. Berchem G Noman MZ Bosseler M Paggetti J Baconnais S Le Cam E Nanbakhsh A Moussay E Mami-Chouaib F Janji B Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer Oncoimmunology 2016 5 e1062968 10.1080/2162402X.2015.1062968 27141372 143. Xue M Chen W Xiang A Wang R Chen H Pan J Pang H An H Wang X Hou H Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1 Mol Cancer 2017 16 143 10.1186/s12943-017-0714-8 28841829 144. Li L Li C Wang S Wang Z Jiang J Wang W Li X Chen J Liu K Li C Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype Can Res 2016 76 1770 1780 10.1158/0008-5472.CAN-15-1625